Literature DB >> 16472972

Symptoms of extraesophageal reflux in a community-dwelling sample.

Nadine P Connor1, Kerrin L P Palazzi-Churas, Stacy B Cohen, Glen E Leverson, Diane M Bless.   

Abstract

OBJECTIVES: Extraesophageal reflux disease (EERD) is linked with serious and varied health concerns. The authors' goal was to determine the prevalence of EERD and the effect on health-related quality of life in adults within a large community-based sample. STUDY
DESIGN: Survey study conducted in a community setting.
METHODS: In the Madison, Wisconsin area, 1845 adult subjects were surveyed. Main outcome measures were frequently of GERD and laryngeal symptoms, the Medical Outcomes Trust Short Form 12 (SF-12), Voice Handicap Index (VHI), and Quality of Life in Reflux and Dyspepsia (QOLRAD) questionnaires.
RESULTS: More than 66% of subjects reported either GERD or laryngeal symptoms, and 26% reported both GERD and laryngeal symptoms (which reflect symptoms commonly reported for EERD). In addition, 39% of our sample took medicine for heartburn. Forty-four percent of subjects with both GERD and laryngeal symptoms reported occasional breathing difficulties, and 38% of these subjects reported a voice disorder. Significant reductions in perceived quality of general health, digestive health, and voice-related quality of life were found in subjects with both GERD and laryngeal symptoms, in comparison with subjects manifesting each symptom group alone, or in subjects with no symptoms.
CONCLUSIONS: The presence of GERD and laryngeal symptoms, and their concurrence, was identified in a substantial number of subjects. The GERD and laryngeal symptoms surveyed represent those most commonly reported for EERD. Because EERD has been linked with tissue damage and reductions in health-related quality of life, it is important to identify these persons and provide treatment before progression of the condition.

Entities:  

Mesh:

Year:  2006        PMID: 16472972     DOI: 10.1016/j.jvoice.2005.10.006

Source DB:  PubMed          Journal:  J Voice        ISSN: 0892-1997            Impact factor:   2.009


  8 in total

Review 1.  How to Approach Laryngopharyngeal Reflux: An Otolaryngology Perspective.

Authors:  Vaninder K Dhillon; Lee M Akst
Journal:  Curr Gastroenterol Rep       Date:  2016-08

2.  Simulated reflux decreases vocal fold epithelial barrier resistance.

Authors:  Elizabeth Erickson; Mahalakshmi Sivasankar
Journal:  Laryngoscope       Date:  2010-08       Impact factor: 3.325

Review 3.  How I Approach Laryngopharyngoesophageal Reflux (LPR).

Authors:  Kaleigh Stabenau; Nikki Johnston
Journal:  Curr Gastroenterol Rep       Date:  2021-11-19

Review 4.  ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease.

Authors:  Philip O Katz; Kerry B Dunbar; Felice H Schnoll-Sussman; Katarina B Greer; Rena Yadlapati; Stuart Jon Spechler
Journal:  Am J Gastroenterol       Date:  2022-01-01       Impact factor: 10.864

5.  Baseline impedance via manometry and ambulatory reflux testing are not equivalent when utilized in the evaluation of potential extra-esophageal gastroesophageal reflux disease.

Authors:  Thomas A Zikos; George Triadafilopoulos; Afrin Kamal; Alexander Podboy; Irene S Sonu; Kirsten A Regalia; Monica C Nandwani; Linda A Nguyen; Nielsen Q Fernandez-Becker; John O Clarke
Journal:  J Thorac Dis       Date:  2020-10       Impact factor: 2.895

Review 6.  Clinical Update Findings about pH-Impedance Monitoring Features in Laryngopharyngeal Reflux Patients.

Authors:  Jerome R Lechien
Journal:  J Clin Med       Date:  2022-06-01       Impact factor: 4.964

Review 7.  Pathophysiological mechanisms of extraesophageal reflux in otolaryngeal disorders.

Authors:  Sören Schreiber; Désirée Garten; Holger Sudhoff
Journal:  Eur Arch Otorhinolaryngol       Date:  2008-08-13       Impact factor: 2.503

Review 8.  [Current possibilities and challenges in the diagnosis of laryngopharyngeal reflux].

Authors:  D Runggaldier; J Hente; M Brockmann-Bauser; D Pohl; J E Bohlender
Journal:  HNO       Date:  2021-02-22       Impact factor: 1.284

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.